✦ LIBER ✦

157 Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in recurrent epithelial ovarian cancer

✍ Scribed by A. Gordon; A. Teitelbaum

Book ID: 118620332
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 162 KB
Volume: 1
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(03)90190-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term survival advantage for women t

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

✍ Alan N. Gordon; Margaret Tonda; Steven Sun; Wayne Rackoff 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 305 KB

Trabectedin plus pegylated liposomal dox

Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis

✍ Bradley J. Monk; Thomas J. Herzog; Stanley B. Kaye; Carolyn N. Krasner; Jan B. V 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 709 KB

Cost-minimisation analysis of pegylated

Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain

✍ Ojeda, B; de Sande, L M; Casado, A; Merino, P; Casado, M A 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 89 KB

Pegylated liposmal doxorubicin prolongs

Pegylated liposmal doxorubicin prolongs survival compared to topotecan as second-line treatment in women with platinum-sensitive ovarian cancer

✍ Paul J. Hoskins 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 109 KB

BRCA Mutation Status and Determinant of

BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin

✍ Safra, T.; Borgato, L.; Nicoletto, M. O.; Rolnitzky, L.; Pelles-Avraham, S.; Gev 📂 Article 📅 2011 🏛 American Association for Cancer Research 🌐 English ⚖ 385 KB

Meta-analysis of trials comparing gemcit

Meta-analysis of trials comparing gemcitabine and pegylated liposomal doxorubicin for treatment in women with progressive or recurrent ovarian cancer

✍ Xia Liu; Li Ma; Jinhui Tian; Kehu Yang 📂 Article 📅 2009 🏛 Springer-Verlag ⚖ 338 KB